Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34765995
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Developing inhaled protein therapeutics for lung diseases
#MMPMID34765995
Matthews AA
; Ee PLR
; Ge R
Mol Biomed
2020[]; 1
(1
): 11
PMID34765995
show ga
Biologic therapeutics such as protein/polypeptide drugs are conventionally
administered systemically via intravenous injection for the treatment of diseases
including lung diseases, although this approach leads to low target site
accumulation and the potential risk for systemic side effects. In comparison,
topical delivery of protein drugs to the lung via inhalation is deemed to be a
more effective approach for lung diseases, as proteins would directly reach the
target in the lung while exhibiting poor diffusion into the systemic circulation,
leading to higher lung drug retention and efficacy while minimising toxicity to
other organs. This review examines the important considerations and challenges in
designing an inhaled protein therapeutics for local lung delivery: the choice of
inhalation device, structural changes affecting drug deposition in diseased
lungs, clearance mechanisms affecting an inhaled protein drug's lung
accumulation, protein stability, and immunogenicity. Possible approaches to
overcoming these issues will also be discussed.
free
free
free
